Title |
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
|
---|---|
Published in |
Oncolytic Virotherapy, November 2015
|
DOI | 10.2147/ov.s66081 |
Pubmed ID | |
Authors |
Hiroshi Nakashima, Tran Nguyen, Ennio Antonio Chiocca |
Abstract |
Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi) have been validated for single use or in combination with other drugs in oncologic therapeutics. An even more novel combination therapy with HDACi is to use them with an oncolytic virus. HDACi may lead to an amplification of tumor-specific lytic effects by facilitating increased cycles of viral replication, but there may also be direct anticancer effects of the drug by itself. Here, we review the molecular mechanisms of anti-cancer effects of the combination of oncolytic viruses with HDACi. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Belgium | 1 | 3% |
Unknown | 29 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 23% |
Student > Ph. D. Student | 7 | 23% |
Student > Master | 4 | 13% |
Student > Bachelor | 2 | 7% |
Student > Doctoral Student | 1 | 3% |
Other | 2 | 7% |
Unknown | 7 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 8 | 27% |
Medicine and Dentistry | 4 | 13% |
Agricultural and Biological Sciences | 3 | 10% |
Immunology and Microbiology | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Other | 4 | 13% |
Unknown | 8 | 27% |